{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"48.2","upperLimit":"78.7","value":"64.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with response (complete response \\[CR\\] or partial response \\[PR\\]) according to the revised response criteria for malignant lymphoma per Cheson et al. 2007. CR was demonstrated by disappearance of all evidence of disease in the bone marrow, spleen, liver, and lymph nodes. PR was \\>50% decrease in the sum of product diameters (SPD) for ≤6 target masses for lymph nodes and \\>50% decrease in SPD for a single nodule in greatest transverse diameter for spleen and liver, and no size increase in the lymph nodes, spleen, or liver. The percentage of participants who experience ORR as assessed by the investigator is presented.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.","id":"OG000","title":"Cohort 3: Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)"}],"paramType":"NUMBER","populationDescription":"All participants in Cohort 3 with a baseline efficacy evaluation and at least 1 post-baseline efficacy evaluation.","reportingStatus":"POSTED","timeFrame":"Up to approximately 78.5 months","title":"Objective Response Rate (ORR) in Cohort 3: Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}